3D Tissue Models

Cell Biology: Pfizer

Total Score People Score Events Score
68 64 46
Date Event Presentation Speakers
December 2, 2015 PERSONALISED MEDICINES & BIOMARKERS 2015 Precision Medicine: Are We There Yet? Claudio Carini
September 24, 2013 Stem Cell Biology Stem Cell Biology Ruth McKernan
July 23, 2013 EpiCongress Boston Using Chemical Probes to Aid Epigenetic Target Validation - unpublished data Mark Bunnage
Chairman’s Opening Remarks Mark Bunnage
Chairman’s Closing Remarks & Close of Conference Mark Bunnage
December 8, 2012 54th American Society of Haematology Annual Meeting and Exposition Career-Development Lunch Sessions David A. Roth
December 4, 2012 4th World Epigenetics Summit Epigenetic Protein Families: A New Frontier in Small Molecule Drug Discoverys Paul Fish
November 29, 2011 The 7th annual European Antibody Congress is the worldleading conference addressing critical scientific issues and strategic industry challenges associated with therapeutic mAb development. Free or total therapeutic monoclonal antibody concentration monitoring Bing Kuang
September 19, 2011 The Role of Biomarkers in Clinical Trials A core microRNA signature of lung inflammation in rat and man Sterghios Moschos
March 27, 2011 Autophagy (D1) mTOR at the Crossroads of Cancer Metabolism and Cancer Therapy Robert T. Abraham
January 12, 2011 Antibodies for the 21st Century Immunoconjugates for Oncology: Fewer Barriers to Delivering Cytotoxicity Now? Alejandro D. Ricart
August 25, 2010 Co-Development of Drugs and Diagnostics Diagnostic Test to Screen Non-Small Cell Lung Cancer Tumors for the Presence of Gene Rearrangements Hakan Sakul
August 24, 2010 Enabling Point-of-Care Diagnostics - Moving Towards Rapid Diagnosis Chairperson’s Remarks Hakan Sakul
June 23, 2010 Structure-Based Drug Design An Enriched Structural Kinase Database to Enable Structure-Based Drug Discovery Natasja Brooijmans
May 19, 2010 Engineering Antibodies Use of Disposable Label-Free Real-Time Biosensors in Epitope Binning Monoclonal Antibodies Yasmina Abdiche
May 4, 2010 Biomarker World Congress 2010 Pre-clinical Translational Biomarkers: Enabling Early Predictions Using PK/PD Mark Fidock
April 28, 2010 Kinase Inhibitor Chemistry Structural Bioinformatics-Based Prediction of Selectivity of a p38 MAP Kinase Inhibitor Li Xing
Discovery of PF-04577806, a Potent and Selective PKCbeta Inhibitor Hui Li
Kinetic Analysis of the Enzyme Mechanism and the Allosteric Inhibition of CHK1 Jacques Ermolieff
October 13, 2009 Fourth Annual Drug Repositioning Summit Pfizer Indications Discovery: Separating the Wheat from the Chaff Michael Barratt
September 19, 2009 Nature Chemical Biology Symposium 2009: Chemical Biology in Drug Discovery Session chair: Carolyn Cho
August 26, 2009 Affinity Tag Protein Purification Self-Cleaving Tags Based on Engineered Inteins: Recent Results and Future Prospects David C. Wood
Lore of the Tag: Affinity Purification of Proteases and Kinases Alfredo Tomasselli
Novel Alternatives to Tag-based Affinity Purification Jeffrey S Culp
August 24, 2009 Fifth Annual Optimizing Cell Culture Technologies Using Systematic Metabolite Analysis to Guide Cell Culture Process Optimization Zhaohui Geng
A Scalable Human Adipocyte Model for the Study of Insulin Resistance Deb Nathan
August 5, 2009 Targets in Context - Linking Targets to Diseases Agenda Human Genetics and Disease Relevant Targets: Linking Clinical Outcomes to Targets Albert B. Seymour
RNAi in Practice Ð Assays and Screening in Mammalian Cells Steven Haney
Tissue Engineered Tumor Niches as Drug Testing Platforms Eric YH Park
August 5, 2009 Drug Safety Strategies to De-Risk Compounds Imaging Techniques for Assessing Toxicity in Primary Human Hepatocytes Eric Tien
Imaging for Hepatotoxicity Eric Tien
Drug-Induced Mitochondrial Dysfunction Yvonne Will
June 22, 2009 Collaborative Innovation in Biomedicine Shared Development of Tools and Technology Erik Kuja
Enlight Biosciences and Related Examples: Pre-competitive Collaboration to Ensure Development and Acceptance of Critical New Technology Erik Kuja
June 16, 2009 4th Annual Cell Based Assays Tackling the challenges of ion channels: developing assays to bridge the gap between experiments and patients Dermot O' Callaghan
Opening remarks from the Chairperson Darren Cawkill
Big isn't always beautiful: effective hit identification using subset screening for ion channels Helen Boyd
Closing remarks from the Chairperson Darren Cawkill
June 10, 2009 Second Annual Hepatotoxicity and Drug Safety In Vitro - In Vivo Correlations of Drug-Induced Liver Injury Jinghai Xu
Strategies to Reduce NCE Hepatotoxicity Attrition Due to Mitochondrial Toxicity- Designing Novel Screening Methods Sashi Nadanaciva
June 9, 2009 RNAi for Target Identification and Validation I. Surveying RNAi Opportunities: From Tools to Therapies Arthur M. Krieg
Chairperson’s Remarks Albert B. Seymour
Human Genetic Approaches to Target Discovery and Validation: Starting With the Clinical Endpoint of Interest Albert B. Seymour
June 4, 2009 Structure-Based Drug Design Using Thermodynamic Information to Enhance Quality of Design in Lead Generation Andrew D. Scott
Thinking Out Loud, a Day One Closing Panel: Are we ready for a GPCR structural explosion? Tomi Sawyer
Improving the Quality of Structure-Based Virtual Screen by The Interaction-Focused Post-Docking Analysis Suo-Bao Rong, Brian S. Bronk
Chairperson’s Remarks Tomi Sawyer
June 3, 2009 Inaugural Drug Induced Liver Injury Development of animal models of idiosyncratic DILI using genomic signatures of susceptibility Husam S Younis
March 23, 2009 StemCONN: Connecticut's International Stem Cell Research Symposium Translation to Clinic Workshop John D. McNeish
February 23, 2009 Advances and Progress in Drug Design VIII VIRTUAL SCREENING IN DRUG DISCOVERY: WHERE IS IT NOW? Alexander Alex
December 2, 2008 2nd Annual Lead Discovery Summit 2008:--Primary & Secondary Screening Cycle management and alignment of operational groups: Optimising discovery by reducing SAR cycle time Wilma Keighley,
Experience and data from the use of cryopreserved cells in screens: Maximising efficiency Peter Stacey,
December 1, 2008 9th Annual Conference E U R OT I D E S 2008 “20 years of oligonucleotide drug development - what do we have to show?” Arthur M. Krieg
TRACK 1: Immune activation by DNA and RNA, implications for hybridization-based oligo(ribo)nucleotide therapies Jörg Vollmer,
March 25, 2008 R&D Risk Mitigation Adapting to a Shifting Industry: How Are Deals Evolving? Stefanie A Hansen
March 25, 2008 Preclinical Development Development of an in Vitro Cytokine Release Assay and its Predicative Value Jing Min
March 25, 2008 TRANSLATIONAL MEDICINE Challenges and Opportunities in Translational Oncology Dominic Spinella
Chairperson’s Remarks Dominic Spinella
January 13, 2008 Chemokines and Chemokine Receptors Chemokines as Targets for Pharmacological Intervention Elna Van Der Ryst
December 4, 2007 7th World Drug Discovery & Development Summit 2007 SYSTEMS BIOLOGY IN DRUG DISCOVERY AND DEVELOPMENT - FUTURE PROMISE AND APPLICATIONS Dr. David De Graaf
Conference room 2 HIGH CONTENT SCREENING Jinghai Xu
November 29, 2007 Cell Signalling and Novel Cancer Therapeutics Role of translational biology in MEK inhibitor development Judith Sebolt Leopold
November 7, 2007 Srial II: Advances and Challenges Toward Major Diseases: Extension on New Hope Nov (07-13) Session 16: Protein and Peptide Drug Development (13:30-17:00) Anton Fliri, Xing Wang
Session 16: Studies on the Origin of Protein Network Topologies (14:50-15:10) Anton Fliri
Session 16: Analytical Challenges in Protein Therapeutics Development (13:30-13:50) Xing Wang
October 17, 2007 Exploring Next Generation Sequencing: Applications and Case Studies (Oct 17-18) Deep Sequencing: Deep Sequence Analysis of Clinically Relevant env Region Sequence Variants from HIV (13:35-14:05) Marilyn Lewis
Deep Sequencing (12:00-15:30) Marilyn Lewis
October 16, 2007 Fifth Annual RNAi for Drug Discovery and Therapeutics - Best Practices from the Bench to the Clinic Oct (16-17) Keynote Introduction; Executive Panel: Delivering Drugs for Difficult Targets (08:40-09:40) Alexander Rod MacKenzie
October 15, 2007 Thirs Annual Quantitative PCR, MicroArrays, And Biologican Validation: Capturing the Complete Biological Story (Oct 15-17) Case Studies: Leveraging Multiple RNA Measurement Tools to Support Discovery Research Programs (16:00-16:30) Shelley Ann Des Etages
Case Studies (15:30-17:30) Shelley Ann Des Etages
October 15, 2007 Cambridge Healthtech Institute's Third Annual Mastering Process Chemistry Oct (15-17) CASE STUDIES OF PRACTICAL SYNTHESIS: Process Development and Scale-Up of AG035029, a Potent PPARg Agonist for Treatment of Type II Diabetes (13:40-14:10) Shu Yu
CASE STUDIES OF PRACTICAL SYNTHESIS: From First Bulk to a Commercial Route: Evolution of the Torcetrapib Process (16:10-16:40) Matt Weekly
October 11, 2007 Compound Profiling & Chemogenomic Approaches to Drive Decision Making and Predict Clinical Adverse Effects (Oct 11-12) SELECTING LEADS AND DETECTING ADVERSE ACTIVITY (14:00-17:30) William T. Loging
SELECTING LEADS AND DETECTING ADVERSE ACTIVITY: Analysis of Drug Induced Effect Patterns for Investigating Systems Structure Effect Relationships (14:35-15:05) William T. Loging
October 10, 2007 Drug Repositioning Summit: Finding New routes to success (Oct 10-11) OVERVIEW SESSION (12:00-15:15) Donald E. Frail
OVERVIEW SESSION: Integration of “Indications Discovery” Efforts within Pfizer (14:15-14:45) Donald E. Frail
REPROFILING DRUGS (08:30-13:30) Donald E. Frail
REPROFILING DRUGS: Panel Discussion - IP and Practical Issues of Drug Repositioning and Repurposing (11:15-12:00) Donald E. Frail
September 17, 2007 Optimizing Cell Culture Development (Sep17-18) OPTIMIZING CELL LINES (08:30-10:50) S. Edward Lee
OPTIMIZING CELL LINES: An Alternative Method for Cell Line Adaptation (09:05-09:35) S. Edward Lee
September 17, 2007 Biomarker Discovery Summit: Bridging the Silos in Biomarker Discovery & Validation (Sep17-19) Third Annual Toxicity Biomarkers; TOXICITY BIOMARKER DISCOVERY (08:30-11:00) Frances Clemo
Third Annual Toxicity Biomarkers; TOXICITY BIOMARKER DISCOVERY: Preclinical Biomarkers of Hepatotoxicity: What’s new? (09:35-10:05) Frances Clemo
Pre-Conference Workshops; Biomarker Assay Development and Validation: Part I Tutorial FIT-FOR-PURPOSE BIOMARKER ASSAY DEVELOPMENT AND VALIDATION (08:00-12:00) Jean W Lee
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.